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Tricuspid regurgitation (TR) is a heterogeneous disorder 
defined by the backflow of blood from the right 
ventricle into the right atrium, what in normal 
conditions should be avoided by systolic leaflets 
coaptation. In almost 90% of TR cases, the valve is 
anatomically preserved, and the regurgitation is 
secondary to right ventricular or right atrial dilation 
(functional TR) due to left-sided heart disease, atrial 
fibrillation, or pulmonary hypertension, culminating in 
tricuspid annular dilation or leaflet tethering. 
The presence of some TR degree is considered the most 
common valvular heart disease, affecting from 65 to 
85% of the population [1], what means a 1.6 and 3.0 
million individuals prevalence, and a 200.000 and 
300.000 yearly incidence in the United States and 
Europe, respectively [2]. If considered only significant 
TR (moderate/severe), the prevalence is one in 25 
individuals with 75 years old and over, similar to that 
observed in significant aortic stenosis [3], and probably 
underestimated, owing to its long clinically silent time 
(no specific murmur or symptoms). Still regarding age, 
it is remarkable that this variable is not only a predictor 
of TR, but it is also associated with worse outcomes and 
increased TR recurrence after surgical treatment [4]. 
Despite its high prevalence and the implied two-fold 
increase in mortality [5], more than 90% of the patients 
with significant TR will never receive surgical 
management [2,6], the only treatment considered class I 
recommendation in the current guidelines. Two main 
reasons are responsible for this undertreatment. The first 
is an obsolete belief that functional TR should improve 
or disappear after the primary left-sided problem 
treatment, which was refuted by well-conducted studies 
proving that TR remains or progresses after left-sided 
interventions [7]. The second is an unacceptable high 
morbimortality rate associated with conventional TR 
surgery, what, unfortunately, remains at least partially 
true, since TR carries the highest surgical mortality 
among all cardiac valve surgeries (8.8% – 9.7%) [4]. 
However, such a bad reputation is in part biased by the 
advanced stage that patients are referred to surgery, 
with severe right ventricle dysfunction and end-organ 
damage, totally opposed to left-sided valves, where 
surgery is performed before the onset of left ventricle 
dysfunction or symptoms. 
Efforts to change the paradigm of poor outcomes related 
to TR management,  and  to  reduce the gap between the  






number of affected and the number of treated patients, 
make the engagement of the “forgotten” valve in the 
transcatheter intervention era an urgent necessity, and a 
new field for device development and clinical research.  
In this scenario, the recent paper published by 
Taramasso et al. [8] “Transcatheter versus medical 
treatment of symptomatic severe tricuspid regurgita-
tion” brings some scientific light over a relatively 
unexplored issue.   
In this propensity-matched case-control study the 
treated group was derived from the TriValve 
(Transcatheter Tricuspid Valve Therapies) registry, the 
largest multicenter, multidevice cohort of patients 
submitted to transcatheter therapies; while the control 
was gathered from two large retrospective registries in 
Europe and North America, providing a high degree of 
reliability and validity to the study. 
Summarizing the main outcomes, the authors showed 
that transcatheter tricuspid valve interventions (TTVI) 
was associated with lower rates of 1-year re-
hospitalization due to heart failure (26±3% vs. 
47±3%; p<0.0001), as well as reduced 1-year mortality 
(23±3% vs. 36±3%; p=0.001), and the composite 
endpoint of death or heart failure rehospitalization 
(32±4% vs. 49±3%; p=0.0003). The composite endpoint 
benefit remained statistically significant even after 
adjusting for sex, New York Heart Association (NYHA) 
class, right ventricular dysfunction, and atrial 
fibrillation (HR 0.39, 95% CI 0.26 – 0.59; p<0.0001). A 
similar magnitude of effect could be observed after 
further adjustment for mitral regurgitation and 
pacemaker/defibrillator implanted (HR 0.35, 95% CI 
0.23 – 0.54; p<0.0001). 
Another notable observation was that in those patients 
who hadn’t a substantial TR reduction after TTVI, the 
outcomes were similar to the control group, indicating 
that TR reduction significantly impacted outcomes 
(heart failure rehospitalization: 41.8% vs. 45.9%; 1-year 
mortality: 27% vs. 35%).  
Regardless the diversity of devices utilized in the study, 
procedural success, defined as patient alive at the end of 
the procedure, with device successfully implanted, 
delivery system retrieved, and residual TR <3+, 
occurred in 86% of patients and did not differ between 
the adopted approaches (p=0.8). 
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To realize the importance of this study in the present 
era, we need first to understand that TR is far from 
being merely a marker of concurrent cardiac disorders. 
Instead of this, TR is a real public health crisis, 
affecting millions of patients, leading to severe heart 
failure and excess mortality and treated only in a 
minimal fraction of affected patients [6]. 
In view of the lack of randomized clinical trials 
evaluating the role of TTVI in symptomatic severe TR 
patients, especially elderly, this paper constitutes 
pioneer evidence supporting a more interventional 
approach, suggesting that it could be the time to change 
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